

Short Communication

Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening[☆]

Steven Keiles^a, Ruth Koepke^b, Richard Parad^c, Martin Kharrazi^{b,*}
California Cystic Fibrosis Newborn Screening Consortium

^a Ambry Genetics, 100 Columbia #200, Aliso Viejo, CA 92656, United States

^b Genetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, United States

^c Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States

Received 23 September 2011; accepted 25 November 2011

Available online 30 December 2011

Abstract

We examined the relation between the number of (TG) repeats at the (IVS8)-(TG)m(T)n locus of the CFTR gene with neonatal serum immunoreactive trypsinogen (IRT) and sweat chloride (SC) concentrations in hypertrypsinogenemic infants with genotype $\Delta F508$ -9T/5T identified by California cystic fibrosis newborn screening. SC and IRT distributions increased with increasing (TG) repeats.

© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Keywords: Newborn screening; CFTR mutation; Diagnosis; Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutation; Poly T

1. Introduction

Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene [1–3]. While over 1800 CFTR mutations have been identified [4], few are well-described as disease-causing. Two polymorphic tracts ((TG)m(T)n) in intron 8 (IVS8) have been shown to affect exon 9 splicing efficiency. Lower numbers of (T) (5 vs. 7 or 9) and higher numbers of (TG) (13 or 12 vs. 11) repeats result in fewer copies of the full transcript and decreased synthesis of functional CFTR protein [5,6]. CF [7], CFTR-related disorders [7], and CFTR-related metabolic syndrome (CRMS) [8] are reportedly more common among those carrying 5T with (TG)13 or (TG)12 compared to (TG)11.

Few have investigated the relation of these haplotypes with CF diagnostic (sweat chloride (SC)) [9,10] and newborn screening (CFNBS) (immunoreactive trypsinogen (IRT)) [9,11–14] tests. We sought to determine the relation of number of (TG) repeats at the (TG)m(T)n locus of CFNBS-identified hypertrypsinogenemic (HT) infants with genotype $\Delta F508$ -9T/5T ($\Delta F508$ in *trans* with only a 5T allele and no other CFTR mutation) with IRT and SC. We also explored the relation of IRT levels with (T) length in *trans* with $\Delta F508$ -9T.

2. Methods

Subjects were identified during the first 2.5 years of California (CA) CFNBS by the CA 4-Step method: Step 1: IRT quantified by AutoDELFIA[®] Neonatal IRT L (PerkinElmer) in all newborn blood spot specimens. Step 2: CFTR mutation analysis (29–40 mutations; Asuragen Signature[®] CF 2.0 ASR) on specimens with IRT ≥ 62 ng/mL (highest 1.5%). Step 3: CFTR full gene sequence analysis utilizing scanning–sequencing technology (Ambry Test[®]:CF) [15] for specimens with only one mutation detected in Step 2. Exon 9 is sequenced for all specimens, allowing for analysis of IVS8 (T) and (TG) [2]. Step 4: SC testing, per national guidelines [16], and follow up

[☆] A version of this material with a smaller population was presented as a poster at the North America Cystic Fibrosis Conference in Minneapolis, Minnesota on October 15–17, 2009 and published as an abstract in *Pediatric Pulmonology Supplement* (2009, Suppl 32: 276).

* Corresponding author at: Genetic Disease Screening Program, California Department of Public Health, 850 Marina Bay Parkway, Room F175, Richmond, CA 94804, United States. Tel.: +1 510 412 1480; fax: +1 510 412 1511.

E-mail address: Marty.Kharrazi@cdph.ca.gov (M. Kharrazi).

by CF Care Centers for infants with two or more mutations, including 5T. When SC results were available from both arms, the higher SC value was recorded. Multiple SC tests were performed over time per CRMS follow-up guidelines [8].

Subjects were included in the $\Delta F508$ -9T/5T cohort if they had one copy of $\Delta F508$ detected during Step 2 and only the IVS8 9T/5T genotype identified during Step 3. Because $\Delta F508$ is almost always in *cis* with 9T [17], $\Delta F508$ was considered to be in *trans* with 5T and 7T alleles.

The distributions of IRT, initial SC (occurring at age (days), median: 57, range 35–159), and highest SC were analyzed by (TG) tract length among those in the $\Delta F508$ -9T/5T cohort. In a separate analysis, we compared IRT among HT infants with genotypes $\Delta F508$ -9T/5T, $\Delta F508$ -9T/7T and $\Delta F508$ -9T/9T.

Univariate statistics, box plots, and scatter plots were generated using SAS version 9.1 (Cary, NC). Differences in distributions of IRT and SC were tested using the Kruskal–Wallis and Mann–Whitney U tests.

3. Results

Among HT infants identified between 7/16/2007 and 1/15/2010, 75 met the inclusion criteria for the $\Delta F508$ -9T/5T cohort. (TG)11 was the most common allele (54%; n=41), followed by (TG)12 (31%; n=23), and (TG)13 (15%; n=11). Twelve (16%) subjects did not have SC results available due to: death unrelated to CF (n=1), insufficient quantity (n=5), and missed appointment (n=6). Among subjects with SC results, 49% (n=31) had one, 43% (n=27) had two, 6% (n=4) had three, and 2% (n=1) had four successfully completed tests.

Initial and highest SC increased with (TG) tract length (Fig. 1). For both initial and highest SC, differences in distributions between all (TG) subgroups reached statistical significance at the $\alpha=0.05$ level and, when combined together, the difference in SC between groups (TG)12 and (TG)13 compared to group (TG)11 was even less likely due to chance alone ($p<0.001$). Among subjects with (TG)11, none had the highest SC ≥ 40 mmol/L. Among subjects with (TG)12, 5% (n=1) had




Fig. 1. Initial and highest SC (mmol/L) measurements among subjects with genotype $\Delta F508$ -9T/5T by 5T-(TG) group. Fig. 1 displays box and whisker plots of the initial and highest SC (mmol/L) measurements of study subjects with genotypes $\Delta F508$ -9T/5T-(TG)11, $\Delta F508$ -9T/5T-(TG)12 and $\Delta F508$ -9T/5T-(TG)13. [Lower and upper “whiskers” represent the lowest and highest values, respectively, within the lower and upper fences (1.5 times the interquartile range (IQR)). The lower edge, midline, and upper edge of the boxes represent the 25th, 50th, and 75th percentiles and the plus sign designates the mean. Outliers beyond 1.5 times the IQR are shown as boxes.] The values for the mean, median, minimum and maximum SC are presented in the accompanying table. Inset graphs display the change in SC measurements with age at sweat test for groups (TG)11-5T, (TG)12-5T, and (TG)13-5T, respectively. Solid lines connect repeated SC measurements for each subject with ≥ 2 SC results.

the highest SC ≥ 40 mmol/L. Among subjects with (TG)13, 30% (n=3) had the highest SC ≥ 40 mmol/L (one subject had SC=60 mmol/L).

SC concentration remained relatively constant with age in the (TG)11 group while the (TG)12 group showed more variability (Fig. 1 inset). All but one (TG)13 subject with multiple SC results demonstrated an increase over time (most increasing to ≥ 40 mmol/L).

IRT increased with decreasing (T) length. Among subjects with 5T, IRT increased with increasing (TG) length (Fig. 2). The distribution of IRT did not differ significantly between the 9T and 7T groups. Subjects with the 5T allele, as a group, had higher IRT values (median=80.5 ng/mL) than the group of subjects with the 9T or 7T allele ($p=0.01$). Among those with 5T, the trend of increasing IRT levels with increasing number of (TG) repeats did not reach statistical significance ($p=0.18$).

4. Discussion

This is the first study to prospectively assess IRT and SC by (TG) number in a relatively large cohort of HT $\Delta F508$ -9T/5T infants systematically identified by CFNBS. Thorough genotyping was performed on all subjects, minimizing the likelihood that IRT and SC results were confounded by undetected

CFTR mutations. While this study was restricted to individuals with 5T in *trans* with $\Delta F508$, we believe these results are generalizable to other disease-causing CF mutations in *trans* with 5T.

The observed increased SC in association with more (TG) repeats supports the hypothesis that the 5T allele phenotype can be modified by (TG) tract length [7]. In addition, the significant proportion of infants with SC in the indeterminate or abnormal range (>40 mmol/L) suggests that (TG)12-5T and (TG)13-5T may act as CF disease-causing mutations. This hypothesis is supported by reports of children and adults with (TG)12-5T or (TG)13-5T *trans* to a known CF disease-causing mutation who have elevated SC and symptoms consistent with CF [18–20]. SC increases during the first year after birth in genotype $\Delta F508$ /(TG)13-5T. Therefore, CFNBS algorithms relying on a single SC measurement to confirm a positive CFNBS result may improperly rule out CF in infants with this genotype.

Previous studies relating IRT to (T) length have found a higher prevalence of the 5T allele among newborns with elevated neonatal IRT [9,12]. In a large Massachusetts CFNBS cohort, a 3-fold increase in 5T allele frequency was seen in infants with IRT above the 90th percentile relative to below it [13]. Our data indicate that even among infants with very elevated IRT (≥ 98.5 th percentile), IRT increases with decreasing




Fig. 2. Distribution of neonatal IRT (ng/mL) among subjects with genotypes $\Delta F508$ -9T/9T, $\Delta F508$ -9T/7T, and $\Delta F508$ -9T/5T-(TG)m. Fig. 2 displays box and whisker plots and summary statistics of the distribution of neonatal IRT (ng/mL) in subjects with genotypes $\Delta F508$ -9T/9T, $\Delta F508$ -9T/7T, $\Delta F508$ -9T/5T-(TG)11, $\Delta F508$ -9T/5T-(TG)12, and $\Delta F508$ -9T/5T-(TG)13. [Lower and upper “whiskers” represent the lowest and highest values, respectively, within the lower and upper fences (1.5 times the IQR). The lower edge, midline, and upper edge of the boxes represent the 25th, 50th, and 75th percentiles and the plus sign designates the mean. Outliers beyond 1.5 times the IQR are shown as boxes.] Fourteen outliers above 140 ng/mL were excluded from the drawing of the box plots but included in the accompanying table: one with 9T, nine with 7T, three with (TG)11-5T, and one with (TG)13-5T. The values for the mean, median, minimum and maximum IRT are presented in the accompanying table.

(T) length. Our data also indicate that IRT may increase with increasing (TG) length. As a result, studies of the association between IRT and the 5T allele should account for (TG) length in *cis* with 5T.

As previous studies have shown, the 5T allele can be a CF disease-causing mutation. In order to better understand the significance of a 5T allele, the length of the accompanying (TG) tract must be determined. When evaluating an infant with a positive CFNBS result for whom a CF diagnosis is unclear, it is important to fully assess the (TG)_m(T)_n loci.

Acknowledgements

We thank the members and staff of the California CF Newborn Screening Consortium for collection of sweat chloride test results: Arnold Platzker, Children's Hospital Los Angeles; Carlos Milla, Lucile S. Packard Children's Hospital; Mark Pian, Rady Children's Hospital San Diego; Reddivalam Sudhakar, Children's Hospital Central California; Christopher Landon, Ventura County Medical Center; Karen Hardy, Children's Hospital Oakland; Bruce Nickerson, Children's Hospital Orange County; Gregory Shay, Kaiser Northern California; Muhammad Saeed, Kaiser Southern California; Yvonne Fanous, Loma Linda University Medical Center; Eliezer Nussbaum, Miller Children's Hospital; Myrza Perez, Sutter Memorial Hospital; Sanjay Jhawar, University of California-Davis Medical Center; and Dennis Nielson, University of California-San Francisco Medical Center.

The authors have no potential conflicts of interest to declare.

The original production of this manuscript did not receive support from an honorarium, grant, or other payment.

References

- [1] Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* 1989;245:1059–65.
- [2] Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. *Science* 1989;245:1073–80.
- [3] Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 1989;245:1066–73.
- [4] Cystic Fibrosis Mutation Database [updated 2011 April 25; cited 2011 May 13]. Available from: <http://www.genet.sickkids.on.ca/cftr/app>.
- [5] Niksic M, Romano M, Buratti E, Pagani F, Baralle FE. Functional analysis of *cis*-acting elements regulating the alternative splicing of human CFTR exon 9. *Hum Mol Genet* 1999;8:2339–49.
- [6] Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)_m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. *J Clin Invest* 1998;101:487–96.
- [7] Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Des Georges M. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. *Am J Hum Genet* 2004;74:176–9.
- [8] Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. *J Pediatr* 2009;155:S106–16.
- [9] Castellani C, Bonizzato A, Mastella G. CFTR mutations and IVS8-5T variant in newborns with hypertrypsinaemia and normal sweat test. *J Med Genet* 1997;34:297–301.
- [10] Massie RJ, Wilcken B, Van Asperen P, Dorney S, Gruca M, Wiley V, et al. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. *J Pediatr* 2000;137:214–20.
- [11] Massie J, Du Sart D, Forshaw K, Carlin J, Forrest SM. The relationship between neonatal immunoreactive trypsinogen, deltaF508, and IVS8-5T. *J Med Genet* 2000;37:629–32.
- [12] Chin S, Ranieri E, Gerace RL, Nelson PV, Carey WF. Frequency of intron 8 CFTR polythymidine sequence variant in neonatal blood specimens. *Lancet* 1997;350:1368–9.
- [13] Parad RB, Comeau A, Harrison E, Gerstle-Thompson J, Eaton R. Newborn cystic fibrosis (CF) carriers are at increased risk for hypertrypsinemia: does this suggest subclinical pancreatic disease in CF carriers? *E-PAS* 2000:1433.
- [14] Scotet V, De Brackeleer M, Audrezet MP, Lode L, Verlingue C, Quere I, et al. Prevalence of CFTR mutations in hypertrypsinaemia detected through neonatal screening for cystic fibrosis. *Clin Genet* 2001;59:42–7.
- [15] Kammesheidt A, Kharrazi M, Graham S, Young S, Pearl M, Dunlop C, et al. Comprehensive genetic analysis of the cystic fibrosis transmembrane conductance regulator from dried blood specimens—implications for newborn screening. *Genet Med* 2006;8:557–62.
- [16] LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel Jr PJ. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. *J Pediatr* 2007;151:85–9.
- [17] Kiesewetter S, Macek Jr M, Davis C, Curristin SM, Chu CS, Graham C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. *Nat Genet* 1993;5:274–8.
- [18] Padoan R, Genoni S, Moretti E, Seia M, Giunta A, Corbetta C. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis. *Acta Paediatr* 2002;91:82–7.
- [19] Van Hoorenbeeck K, Storm K, van den Ende J, Biervliet M, Desager KN. N1303K and IVS8-5T, clinical presentation within a family with atypical cystic fibrosis. *J Cyst Fibros* 2007;6:220–2.
- [20] Noone PG, Pue CA, Zhou Z, Friedman KJ, Wakeling EL, Ganeshanathan M, et al. Lung disease associated with the IVS8 5T allele of the CFTR gene. *Am J Respir Crit Care Med* 2000;162:1919–24.